Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Orexin Receptor Type 2 Treatment Pipeline Review H2 2016

Wednesday, October 26, 2016 5:32
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Pipeline Review, H2 2016’, provides in depth analysis on Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/711796-orexin-receptor-type-2-hypocretin-receptor-type-2-or-hcrtr2-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) 
- The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Complete report details @ https://www.wiseguyreports.com/reports/711796-orexin-receptor-type-2-hypocretin-receptor-type-2-or-hcrtr2-pipeline-review-h2-2016      

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 5 
Introduction 6 
Report Coverage 6 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Overview 7 
Therapeutics Development 8 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Products under Development by Stage of Development 8 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Products under Development by Therapy Area 9 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Products under Development by Indication 10 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Pipeline Products Glance 11 
Late Stage Products 11 
Early Stage Products 12 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Products under Development by Companies 13 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Therapeutics Assessment 15 
Assessment by Monotherapy/Combination Products 15 
Assessment by Mechanism of Action 16 
Assessment by Route of Administration 18 
Assessment by Molecule Type 19 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Companies Involved in Therapeutics Development 20 
Eisai Co., Ltd. 21 
Evotec AG 22 
Heptares Therapeutics Limited 23 
Johnson & Johnson 24 
Merck & Co., Inc. 25 
Novartis AG 26 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Drug Profiles 27 
DORA-12 – Drug Profile 27 
Product Description 27 
Mechanism Of Action 27 
R&D Progress 27 
HTL-6641 – Drug Profile 28 
Product Description 28 
Mechanism Of Action 28 
R&D Progress 28 
JNJ-42847922 – Drug Profile 29 
Product Description 29 
Mechanism Of Action 29 
R&D Progress 29 
lemborexant – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
MK-8133 – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders – Drug Profile 37 
Product Description 37 
Mechanism Of Action 37 
R&D Progress 37 
Small Molecule to Antagonize Orexin Receptor Type 1 and 2 for Insomnia – Drug Profile 38 
Product Description 38 
Mechanism Of Action 38 
R&D Progress 38 
Small Molecule to Inhibit OX2R for Insomnia – Drug Profile 39 
Product Description 39 
Mechanism Of Action 39 
R&D Progress 39 
Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy – Drug Profile 40 
Product Description 40 
Mechanism Of Action 40 
R&D Progress 40 
suvorexant – Drug Profile 41 
Product Description 41 
Mechanism Of Action 41 
R&D Progress 41 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Dormant Projects 44 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Discontinued Products 45 
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) – Featured News & Press Releases 46 
Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia 46 
Jun 01, 2016: Minerva Neurosciences to Present data on MIN-202 47 
Mar 11, 2016: Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202 47 
Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients 48 
Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase 2A Clinical Trial in Insomnia Disorder 49 
Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial With Central Nervous System Product Candidate MIN-202 49 
Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist 50 
Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist 50 
Feb 03, 2015: Merck’s Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States 51 
Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 52 
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance 53 
Nov 26, 2014: Merck announces launch of Berusomura tablets15mg/20mg in Japan 54 
Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 54 
Aug 13, 2014: FDA Approves BELSOMRA for the Treatment of Insomnia 55 
Jul 01, 2013: Merck Receives Complete Response Letter for Suvorexant, Merck’s Investigational Medicine for Insomnia 57 
Appendix 58 
Methodology 58 
Coverage 58 
Secondary Research 58 
Primary Research 58 
Expert Panel Validation 58 
Contact Us 58 
Disclaimer 59

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=711796

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.